403 related articles for article (PubMed ID: 16184587)
1. Bone mineral density and serum bone turnover markers in survivors of childhood acute lymphoblastic leukemia: comparison of megadose methylprednisolone and conventional-dose prednisolone treatments.
Alikasifoglu A; Yetgin S; Cetin M; Tuncer M; Gumruk F; Gurgey A; Yordam N
Am J Hematol; 2005 Oct; 80(2):113-8. PubMed ID: 16184587
[TBL] [Abstract][Full Text] [Related]
2. No difference between prednisolone and dexamethasone treatment in bone mineral density and growth in long term survivors of childhood acute lymphoblastic leukemia.
van Beek RD; de Muinck Keizer-Schrama SM; Hakvoort-Cammel FG; van der Sluis IM; Krenning EP; Pieters R; van den Heuvel-Eibrink MM
Pediatr Blood Cancer; 2006 Jan; 46(1):88-93. PubMed ID: 15926166
[TBL] [Abstract][Full Text] [Related]
3. [Accretion of bone mass in patients treated for childhood acute lymphoblastic leukemia].
Muszyńska-Rosłan K; Konstantynowicz J; Krawczuk-Rybak M
Pol Merkur Lekarski; 2007 Oct; 23(136):271-5. PubMed ID: 18293849
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects of growth hormone (GH) on bone mineral status and bone turnover markers in patients with isolated GH deficiency and multiple pituitary hormone deficiency.
Gonc EN; Kandemir N
Clin Endocrinol (Oxf); 2007 May; 66(5):672-7. PubMed ID: 17381489
[TBL] [Abstract][Full Text] [Related]
5. Improvement in bone mineral density and body composition in survivors of childhood acute lymphoblastic leukemia: a 1-year prospective study.
Marinovic D; Dorgeret S; Lescoeur B; Alberti C; Noel M; Czernichow P; Sebag G; Vilmer E; Léger J
Pediatrics; 2005 Jul; 116(1):e102-8. PubMed ID: 15995009
[TBL] [Abstract][Full Text] [Related]
6. Reduced bone mineral density in young adults following cure of acute lymphoblastic leukaemia in childhood.
Brennan BM; Rahim A; Adams JA; Eden OB; Shalet SM
Br J Cancer; 1999 Apr; 79(11-12):1859-63. PubMed ID: 10206305
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of bone mineral density at different phases of therapy of childhood all.
Maniadaki I; Stiakaki E; Germanakis I; Kalmanti M
Pediatr Hematol Oncol; 2006; 23(1):11-8. PubMed ID: 16326407
[TBL] [Abstract][Full Text] [Related]
8. Benefit of high-dose methylprednisolone in comparison with conventional-dose prednisolone during remission induction therapy in childhood acute lymphoblastic leukemia for long-term follow-up.
Yetgin S; Tuncer MA; Cetin M; Gümrük F; Yenicesu I; Tunç B; Oner AF; Toksoy H; Koç A; Aslan D; Ozyürek E; Olcay L; Atahan L; Tunçbilek E; Gürgey A
Leukemia; 2003 Feb; 17(2):328-33. PubMed ID: 12592331
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of bone metabolism in children with acute lymphoblastic leukemia after induction chemotherapy treatment.
Athanassiadou F; Tragiannidis A; Rousso I; Katsos G; Sidi V; Koliouskas D; Papastergiou C; Tsituridis I
Pediatr Hematol Oncol; 2005 Jun; 22(4):285-9. PubMed ID: 16020115
[TBL] [Abstract][Full Text] [Related]
10. Comparision of the apoptotic effects on lymphoblasts and on increase of myeloid lineage cells of a short-time, high-dose methylprednisolone and the conventional-dose prednisolone treatments in children with acute lymphoblastic leukemia.
Erduran E; Tekelioglu Y; Karakas T; Gedik Y; Mert FM
Pediatr Hematol Oncol; 2006; 23(7):587-98. PubMed ID: 16928654
[TBL] [Abstract][Full Text] [Related]
11. Bone mineral density in long-term survivors of childhood cancer.
Hesseling PB; Hough SF; Nel ED; van Riet FA; Beneke T; Wessels G
Int J Cancer Suppl; 1998; 11():44-7. PubMed ID: 9876477
[TBL] [Abstract][Full Text] [Related]
12. Assessment of bone mineral density and risk factors in children completing treatment for acute lymphoblastic leukemia.
Gunes AM; Can E; Saglam H; Ilçöl YO; Baytan B
J Pediatr Hematol Oncol; 2010 Apr; 32(3):e102-7. PubMed ID: 20216235
[TBL] [Abstract][Full Text] [Related]
13. Skeletal morbidity in childhood acute lymphoblastic leukemia.
Mandel K; Atkinson S; Barr RD; Pencharz P
J Clin Oncol; 2004 Apr; 22(7):1215-21. PubMed ID: 15051768
[TBL] [Abstract][Full Text] [Related]
14. The effect of high-dose methylprednisolone combined chemotherapy on CD34-positive cells in acute lymphoblastic leukemia.
Tuncer AM; Hiçsönmez G; Gümrük F; Albayrak D; Duru F; Güzel E; Sayli T
Hematol Pathol; 1994; 8(4):169-75. PubMed ID: 7532164
[TBL] [Abstract][Full Text] [Related]
15. Osteopenia, physical activity and health-related quality of life in survivors of brain tumors treated in childhood.
Odame I; Duckworth J; Talsma D; Beaumont L; Furlong W; Webber C; Barr R
Pediatr Blood Cancer; 2006 Mar; 46(3):357-62. PubMed ID: 16035080
[TBL] [Abstract][Full Text] [Related]
16. Little evidence of low bone mass in acute lymphoblastic leukemia survivors.
Muszynska-Roslan K; Panasiuk A; Latoch E; Krawczuk-Rybak M; Konstantynowicz J
J Clin Densitom; 2012; 15(1):108-15. PubMed ID: 21880524
[TBL] [Abstract][Full Text] [Related]
17. Altered bone mineral density and body composition, and increased fracture risk in childhood acute lymphoblastic leukemia.
van der Sluis IM; van den Heuvel-Eibrink MM; Hählen K; Krenning EP; de Muinck Keizer-Schrama SM
J Pediatr; 2002 Aug; 141(2):204-10. PubMed ID: 12183715
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the effect of high-dose methylprednisolone with conventional-dose prednisolone in acute lymphoblastic leukemia patients with randomization.
Yetgin S; Gürgey A; Tuncer AM; Cetin M; Ozbek N; Sayli T; Güler E; Kara A; Olcay L; Duru F; Gümrük F; Atahan L; Tunçbilek E
Leuk Res; 1998 Jun; 22(6):485-93. PubMed ID: 9678714
[TBL] [Abstract][Full Text] [Related]
19. [Bone mineral density in children before and after completion of cancer treatment].
Muszyńska-Rosłan K; Konstantynowicz J; Krawczuk-Rybak M; Kaczmarski M; Piotrowska-Jastrzebska J
Pol Merkur Lekarski; 2004 Jul; 17(97):37-42. PubMed ID: 15559608
[TBL] [Abstract][Full Text] [Related]
20. The effect of growth hormone treatment on bone mineral density in prepubertal girls with Turner syndrome: a multicentre prospective clinical trial.
Aycan Z; Cetinkaya E; Darendeliler F; Vidinlisan S; Bas F; Bideci A; Demirel F; Darcan S; Buyukgebiz A; Yildiz M; Berberoglu M; Bundak R
Clin Endocrinol (Oxf); 2008 May; 68(5):769-72. PubMed ID: 17980015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
